Loading
BT
biOasis Technologies Inc. Stock: price and insider trades · Canada
biOasis Technologies Inc.: what insiders have been doing
biOasis Technologies Inc. is a listed company. Its insiders report their share dealings to SEDI. biOasis Technologies Inc. has had no insider filing for more than a year; the last one goes back to 22 May 2019.
Our records for biOasis Technologies Inc. go back to 2016, with 2 purchases and no sales on the open market in total.
Source: insider filings from SEDI. Past trades are no guide to future returns.
Insider Decl.
24
Thresholds
n/a
Buy Volume
n/a
2 ops. · all time
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
Last declaration on 22 May 2019
Declarations24 total
53,500 shares@ CA$0.28100.0% of flowCommon SharesTSXSEDI:3370988
178,571 shares@ CA$0.28100.0% of flowCommon SharesTSXSEDI:3370970
53,571 shares@ CA$0.28100.0% of flowCommon SharesTSXSEDI:3370977
Common SharesTSXSEDI:3370987
Common SharesTSXSEDI:3370976
Common SharesTSXSEDI:3370965
50,000 sharesCommon SharesTSXSEDI:3222248
91,000 sharesCommon SharesTSXSEDI:3185893
Common SharesTSXSEDI:3185892
45,761 sharesCommon SharesTSXSEDI:3184895
Common SharesTSXSEDI:3184894
23,317 sharesCommon SharesTSXSEDI:3184884
Common SharesTSXSEDI:3174550
7,332 sharesCommon SharesTSXSEDI:3174742
Common SharesTSXSEDI:3069977
5,000 sharesCommon SharesTSXSEDI:3069978
Canonical exit: 4 Jan 2018 (T+90)
Common SharesTSXSEDI:3024575
33,000 sharesCommon SharesTSXSEDI:3024578
Canonical exit: 20 Sept 2017 (T+90)
4,618,000 sharesCommon SharesTSXSEDI:2826125
120,000 sharesCommon SharesTSXSEDI:2826150
4,618,000 sharesCommon SharesTSXSEDI:2826149
Common SharesTSXSEDI:2826133
Common SharesTSXSEDI:2783505
150,000 shares@ CA$0.64100.0% of flowCommon SharesTSXSEDI:2783507
24 of 24 declarations
About biOasis Technologies Inc.
biOasis Technologies Inc. is a company focused on developing therapies for neurological diseases. It specializes in utilizing its drug delivery technology to cross the blood-brain barrier.
